Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference50 articles.
1. Rose NR. Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol. 2016. https://doi.org/10.1093/aje/kwv292.
2. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3–4):197–207.
3. Olivieri I, Cortesi PA, de Portu S, PACE Working Group, et al. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016;34(1):68–75.
4. Cooksey R, Husain MJ, Brophy S, et al. The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0126105.
5. Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G. A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S136–41.